Semaglutide-Induced Liver Injury.

Semaglutide, a glucagon-like peptide-1 receptor agonist widely used for managing type 2 diabetes mellitus and obesity. Reports of semaglutide-associated hepatotoxicity are exceedingly rare. We detail a case of a 44-year-old woman who developed liver injury with elevated liver enzymes after semaglutide initiation for weight management.

Efficacy and safety of repeat endoscopic submucosal dissection for recurrent, synchronous, and metachronous esophageal squamous cell carcinoma: a systematic review and meta-analysis.

Background And Aims: Endoscopic submucosal dissection (ESD) is the preferred treatment for early-stage esophageal squamous cell carcinoma (ESCC), providing a minimally invasive endoscopic alternative to surgery with potential for complete resection and organ preservation. This study aims to evaluate the efficacy and safety of repeat ESD for recurrent ESCC lesions located on or near previous ESD scars.

Methods: A systematic search of PubMed, Google Scholar, and Cochrane (from inception to November 2024) identified studies on repeat ESD for recurrent ESCC near previous ESD scars.